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The Effect of Omega 3 Fatty Acids on Atrophic Vaginitis in Breast Cancer Survivors 
Introduction 
 Breast cancer is the most prevalent type of cancer among women in the U.S. which in 
turn has resulted in nearly 5 million breast cancer survivors (Jemal, Ward, Siegel, & Xu, 2010). 
This significant survivorship statistic supports the increased quantity of life that breast cancer 
survivors have experienced. This is contrary to quality of life, which is often overlooked and can 
negatively be affected secondary to side effects imposed by treatment  
 Urogenital atrophy is a process which occurs in postmenopausal breast cancer survivors 
in response to endogenous and exogenous estrogen withdrawal.  Unpleasant symptoms are 
often experienced secondary to the consequences of diagnosis and the life-extending 
treatments of chemotherapy, hormonal therapy, hormone agonists, and ovarian ablation 
(Kelley, 2007; Willhite & O’Connell, 2001).  Urogenital atrophy affects 95% of menopausal 
women; 40% of those women experience moderate to severe symptoms (Carcio, 2010).This 
condition remains under-reported and under-diagnosed as menopausal women typically regard 
their vaginal symptoms as private information and often believe this is an inevitable process of 
aging (Carcio, 2002).  When in the oncology provider’s office, breast cancer survivors often 
rationalize that these symptoms are part of the breast cancer trajectory, they are alive, and 
should not complain. If not assessed by the provider, the topic rarely is discussed (Lester & 
Bernhard, 2009). 
Urogenital Changes with Menopause 
Normal Vaginal Environment 
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Vaginal tissue is primarily squamous cells in the epithelial cell layer which respond to the 
stimulation of male and female hormones.  The estrogen in the vaginal mucosa promotes 
glycogen production; as these glycogen-rich cells shed, the growth of Doderlein’s lactobacilli is 
stimulated.  The lactobilli bacteria produce lactic acid that maintains a vaginal pH of 3.5 to 4.5 
(Carcio, 2002; Castelo-Branco, et al., 2005).  This acidic environment serves as a protective 
mechanism and provides a barrier against pathogenic bacteria. The maturation of vaginal 
epithelial cells is dependent upon the proliferative effects of estrogen which allow for the 
formation of a protective outer vaginal layer.  This layer consists of cornified cells that protect 
the delicate underlying genital structures from injury and infection.  
Atrophic Vaginitis 
Symptoms related to atrophic vaginitis are common in the general postmenopausal 
female population, but are often more prevalent and severe in women treated for breast 
cancer as compared to age-matched women without breast cancer (Conde et al, 2005; Lester & 
Bernhard, 2009; Zibecchi, Greendale, & Ganz, 2003). Atrophic vaginitis is an inflammatory 
condition that involves the lower genitalia and produces vaginal discomfort and pain.  The 
vaginal mucosa becomes dry and thin due to a compromised estrogenic effect with unpleasant 
symptoms of vaginal dryness, burning, itching, and dypareunia (Castelo-Branco, Cancelo, 
Villero, Nohales, & Juliá, 2005).  Vaginal dryness is a common, distressing symptom that occurs 
in 67% of breast cancer survivors (Lester & Bernhard, 2009); genital irritation and itching occur 
in 30% of survivors (Lester& Bernhard, 2009).  A high percentage of breast cancer survivors 
desire sexual activity (79%), although 31% report that vaginal pain is a significant deterrent 
(Lester & Bernhard, 2009).  Therefore, safe and effective interventions must be identified to 
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improve these symptoms and thereby improve the overall quality of life among these survivors.  
Theory of Unpleasant Symptoms 
The theory of unpleasant symptoms can be used to explain a cluster of symptoms that 
are influenced and affected by a multitude of overlapping factors.  The assumption underlying 
the theory is that there are sufficient commonalities among symptoms to warrant a theory that 
is not limited to one symptom, but can explain and guide research for multiple symptoms (Lenz, 
Gift, Pugh & Milligan, 2008). 
 Symptoms are of vital importance in health care and are perceived as indicators of 
change. In the case of atrophic vaginitis, vaginal dryness is often accompanied by genital 
irritation and dyspareunia.  Many qualities of the symptoms are reviewed such as intensity, 
duration, quality and distress which contribute to performance outcomes. In the theory of 
unpleasant symptoms, three categories of variables are identified as influencing the occurrence 
of symptoms: physiologic factors, psychologic factors, and situational factors  (Lenz, et al., 
2008). Physiologic antecedents are often diagnosed by the presence of unpleasant symptoms; 
thus, the influence of physiologic factors on the experience of symptoms is well documented. In 
terms of atrophic vaginal dryness, physiologic evidence of decreased vaginal secretions, thin 
and shiny epithelium, diminished rugae, increased pH, friability, introital stenosis, and 
decreased vaginal elasticity influences the severity of the symptoms experienced by breast 
cancer survivors.  
 The theory of unpleasant symptoms was used to measure the intervention of omega 3 
fatty acids and its mediating effect from treatment-induced physiologic effects on the incidence 
of unpleasant symptoms and performance outcomes. Consistent within the theory, oral omega 
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3 fatty acid supplementation was identified as a mediating effect that may alter the influencing 
physiological factors related to atrophic vaginitis with the intent that there will be a change in 
unpleasant symptoms associated with atrophic vaginitis and improved performance outcomes. 
Urologic Atrophy 
 Atrophy in urethral epithelium results in decreased sensitivity in urethral smooth muscle 
and decreased amounts of collagen in periurethral tissue (Calleja-Agius & Brincat, 2009). 
Urologic complaints from women with symptoms of urethral atrophy include frequency, 
nocturia, urgency, incontinence, and urinary tract infections (Calleja-Agius & Brincat, 2009; 
Castelo-Branco, et al., 2005).   
External Genital Atrophy 
A decreased level of estrogen can negatively affect nearly every structure of the 
external urogenital tract. Common changes in the atrophic vulva include loss of labial and 
vulvar fullness and inflammation of mucosal surfaces.  The vulva undergoes a gradual loss of 
collagen, adipose, and water which lead to decreased turgor and elasticity; in addition, pubic 
hair decreases (Calleja-Agius & Brincat, 2009). As a result of these changes, vaginal ulcerations 
and friability can occur due to a decreased epithelial layer. The vaginal mucosa is more prone to 
tears with decreased elasticity, increased friability, and a loss of protective layers. The increased 
friability can lead to evidence of petechiae, ulcerations, and bleeding secondary to minimal 
friction or trauma (Calleja-Agius & Brincat, 2009; Lester & Bernhard, 2009).  
The introitus may narrow and tighten, and possibly contract with a concomitant 
shortening of the vagina. With the loss of estrogen, the prepuce of the clitoris can atrophy 
(Calleja-Agius & Brincat, 2009). A urinary caruncle can also be present which appears as a red, 
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berry-like protrusion at the urethral meatus (Carcio, 2002.)  Women often experience 
decreased lubrication which may create a burning, itching, or irritating sensation (Carcio, 2002; 
Castelo-Branco, et al., 2005).  The sebaceous glands of the vagina are still present and 
functional in the postmenopausal woman, but the amount of secretions diminishes and the 
ability to provide lubrication during sexual intercourse is often delayed (Ibe & Simon, 2010).  
When sexual activity is attempted under these conditions, it can be a painful and unpleasant 
experience for the woman, as well as the partner. 
Dyspareunia 
Many women experience pain during sexual intercourse due to decreased properties of 
the basal level, reduced vaginal capillary blood flow, and impaired oxygenation of the tissues. 
These deficits result in an inability for the vaginal structures to reach the usual level of 
engorgement during sexual intercourse as compared to an estrogen-primed vagina   (Calleja-
Agius & Brincat, 2009). In addition to dyspareunia, vulvovaginal atrophy appears to also affect 
sexual desire and arousal (Ibe & Simon, 2010).  It remains unknown if this decrease in desire 
and arousal is due to physical causes or due to the woman’s prior experiences of pain during 
foreplay and intercourse (Lester, Bernhard, & Ryan-Wenger, 2012). As the frequency of sexual 
intercourse decreases with their partner, vaginal lubrication further declines (Castelo-Branco, 
2005; Ibe & Simon, 2010).  The lack of estrogen may also cause reduced vestibular sensation, 
which in turn leads to a diminished intensity of orgasmic pleasure (Ibe & Simon, 2010).     
Urogenital Atrophy in Breast Cancer Survivors 
Survival rates for women with breast cancer continue to improve; 89% of the 3.5 million 
women diagnosed with breast cancer reach their five-year survival mark (Jemal et al., 2009).  
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Due to advances in treatment and prevention, the length of life for these women has extended, 
often to decades of disease-free survival. Contrary to these benefits, breast cancer survivors 
may face side effects that are detrimental to their quality of life.  Unpleasant symptoms are 
often experienced as a result of their diagnosis, chemotherapy, hormonal therapy, hormone 
agonists, and ovarian ablation (Lester & Bernhard, 2009).  The diagnosis of breast cancer and 
multiple combinations of treatments often lead women down a rapid path to premature loss of 
ovarian function.  The treatments they receive can either induce or exacerbate menopausal 
symptoms due to reduced estradiol levels that tend to be more severe than in women without 
breast cancer (Lester & Bernhard, 2009).  The life-extended treatments that women receive for 
breast cancer can reduce or eradicate ovarian function which can lead to acute or chronic 
urogenital atrophy.  
Effects of Chemotherapy     
Chemotherapy, specifically with alkylating agents can cause ovarian toxicity, end 
menstrual cycles, and cause dypareunia and vaginal dryness (Lester & Bernhard, 2009). Women 
who receive high-dose chemotherapy are at increased risk for persistent vaginal dryness 
(MacBride, et al., 2010).  Women who are younger than 40 are less likely to experience 
permanent amenorrhea then women aged 40 years or older following chemotherapy.  Young 
women may still experience long-term menstrual irregularities as a result of chemotherapy and 
have a greater risk of premature menopause (Lester & Bernhard, 2009).  These effects all lead 
to a greater likelihood of vaginal atrophy with adverse symptoms secondary to estrogen 
deficiencies. Vaginal symptoms have been reported in 23% to 61% of breast cancer survivors 
(Lester, et al., 2012; MacBride, et al., 2010).  In a study of women treated for breast cancer, 
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sexual issues were reported by 60% of women, urinary issues by 55%, and vaginal dryness by 
55% (Lester & Bernhard, 2009).  These adverse effects can lead to decreased quality of life with 
negative effects on intimate relations.  
Effects of Aromatase Inhibitors 
Aromatase inhibitors (AIs) are prescribed as systemic therapy to women with estrogen 
receptor positive breast cancer.  In a study that compared the side effect outcomes of 
treatment with tamoxifen versus anastrozole, vaginal dryness was more common in the group 
that took anastrozole than in the group with tamoxifen (MacBride, Shuster, & Rhodes, 2010). 
Tamoxifen acts as an estrogen antagonist or agonist depending on the target organs and the 
woman’s menopausal state (MacBride, et al., 2010).  Tamoxifen may actually cause 
vulvovaginal atrophy in premenopausal women through actions as an estrogen antagonist with 
blockage of the naturally high levels of endogenous estrogen (MacBride, et al., 2010).  
However, tamoxifen may conversely act as an estrogen agonist on the urogenital tract in 
postmenopausal women (MacBride, et al., 2010), an ultimate benefit to women.   
Today, aromatase inhibitors are more frequently prescribed in postmenopausal  
 women with hormone receptor-positive breast cancer (Witherby, et al., 2011) with a 
concomitant risk of urogenital atrophy in women with premature menopause secondary to 
chemotherapy, or exacerbated urogenital atrophy in menopausal women (Lester & Bernhard, 
2009).  Vaginal symptoms have been reported in 23% to 61% of breast cancer survivors 
(MacBride, et al., 2010).  In a study of women treated for breast cancer, sexual issues were 
reported in 60% of women, urinary issues in 55%, and vaginal dryness in 55% (Lester & 
Bernhard, 2009).  The leads to a decreased quality of life for these women who are more likely 
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to experience negative effects on their sex lives as a result of poor lubrication, genital pain and 
interference with sexual pleasure (Lester & Bernhard, 2009).   
The third-generation AIs improve survival rates through a further decrease in the levels 
of circulating estrogens.   These drugs cause a profound estrogen depletion that inhibits the 
aromatase enzyme and promotes the conversion of androgens to estrogens in postmenopausal 
women (Biglia, et al., 2010).     
Clinical Evaluation of Urogenital Atrophy 
 It is important to obtain an overall health history from the patient with complaints of 
urogenital atrophy to ascertain changes in overall health status. Subsequently, the history 
should focus on potential or recognized hormonal changes and symptoms related to urogenital 
atrophy. A pelvic examination with a visual exam of the external and internal surfaces of the 
urogenital tract is essential. A cytologic examination of a vaginal smear will establish the level of 
cellular maturation.  The vaginal smear should be obtained from the upper one-third of the 
vagina in order to determine the estrogenic response in the epithelial cells and the overall level 
of cellular maturation (Calleja-Agius & Brincat, 2009; Carcio, 2002).  A vaginal pH will provide 
objective evidence of the postmenopausal vaginal environment (Lester & Bernhard, 2009). 
Cellular Maturation 
 The basal cell layer of the vagina is the least mature layer and is found adjacent to the 
basement membrane (see Figure 2).  When estrogen is present, basal cells evolve into more 
developed forms and accumulate as the cells mature.  Parabasal cells are found above the 
basement membrane which is often the uppermost layer of cells that defines atrophic vaginitis 
(Calleja-Agius & Brincat, 2009; Carcio, 2002).  These cells have large nuclei with a rounded 
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appearance and a smaller portion of cytoplasm (Carcio, 2002).  Contiguous to this layer are the 
intermediate cells; the nuclei become smaller and the cytoplasm increases.  The intermediate 
cells appear flattened and more cuboid (Carcio, 2002).   
 The outer superficial cells are well-differentiated and comprise the most mature layer.  
These are larger, flat, squared-off cells with even smaller nuclei and larger amounts of 
cytoplasm. It takes 7 to 10 days for vaginal epithelial cells to mature; the maturation index 
continually changes in response to the fluctuation of hormones.  To determine therapeutic 
response, it is important to perform serial microscopic smears. There are no published studies 
that demonstrate a direct relationship between the estrogen status and maturation index. 
Therefore, the maturation index should not be used as the sole diagnostic criteria for atrophy 
(Carcio, 2002) and vice versa, the estrogen status is not a sole criterion that defines the 
presence or absence of vaginal atrophy.  
 There is evidence that the presence of parabasal cells is indicative of an estrogen 
deficiency (Carcio, 2002).  The presence/absence of lactobacilli and white blood cells 
[polymorphonuclear cells (PMNs)] should also be observed.  The gram-positive, aerobic non-
spore-forming lactobacilli are easily visible on a wet-mount slide.  An atrophic smear will show 
very few, if any, of these rod-shaped bacilli that usually dominate the flora of the normal 
estrogenized vagina.  The PMNs appear as dark, granular cells with clearly segmented nuclei 
(Carcio, 2002).  When white blood cells are prevalent, they can cause a shift of the maturation 
index that appears more mature as a result of the infection. Women that are sexually active 
tend to have a more mature vaginal epithelium than that of the abstinent woman (Carcio, 2002; 
Castelo-Branco, et al., 2005), as regular sexual activity improves blood circulation to the vagina. 
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In addition, seminal fluid contains sex steroids, prostaglandins, and essential fatty acids which 
serve to enrich vaginal integrity (Castelo-Branco, et al., 2005). 
Vaginal pH is a reliable indicator of atrophic vaginitis and is representative of the acid or 
alkaline setting of the vagina.  The pH is affected by the presence of lactobacilli or other 
organisms in the vaginal environment.  In estrogen deficient women, a dramatic decrease in the 
amount of lactobacilli can be observed which leads to a more alkaline environment.  The pH can 
also be affected by semen and blood which are alkaline in nature.  Women should avoid sexual 
intercourse 3 to 4 days prior to the examination and ensure the end of menses in order to 
provide an accurate evaluation of the vaginal milieu. 
Treatment of Urogenital Atrophy 
Atrophic vaginitis is most commonly treated with estrogen therapy since the sole cause 
is a deficiency of estrogen. The use of estrogen aids in the reversal of atrophic changes and the 
restoration of the vaginal mucosa (Carcio, 2002).  Estrogen replacement for the relief of 
atrophic vaginitis is provided as a systemic estrogen, or with localized vaginal products; a 
combination of the two is often used.  Localized vaginal estrogen products include vaginal 
creams, estradiol vaginal tablets, and an estradiol-releasing vaginal ring (Calleja-Aguis & Brincat, 
2009; Carcio, 2002). In addition, vaginal lubricants and moisturizers can provide short-term 
relief of symptoms. 
Vaginal Lubricants and Moisturizers 
Treatment for women with vaginal atrophic changes is geared toward symptom relief 
and reversal of the atrophic anatomic changes.  The first line treatments include non-hormonal 
vaginal lubricants and moisturizers (Ibe & Simon, 2010) which are intended to provide relief of 
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symptoms. However, the non-hormonal vaginal gel products may also have positive effects on 
vaginal pH and maturation level (Ibe & Simon, 2010).  Vaginal moisturizers provide extended 
relief by changes in the fluid content of the endothelium and a decrease in vaginal pH (Willhite 
& O’Connell, 2001).  Vaginal moisturizers are safe for long-term use, but need to be used on a 
regular basis for optimal effect (MacBride, et al., 2010).  Vaginal water or silicone-based 
lubricants are shorter-acting than moisturizers and are primarily intended for use at the time of 
sexual intercourse for relief of friction-induced discomfort.  The water-based products often 
require repeated applications with a moderate to large amount of lubrication gel, whereas the 
silicone-based products typically require smaller amounts; these may interfere with erectile 
dysfunction in the male partner (MacBride, et al., 2010).  
A recent randomized double blinded study tested the effect of a vaginal pH-balanced gel 
with lactic acid on vaginal atrophy in breast cancer survivors after cancer treatment (Yoo-
Kyung, et al., 2011). The vaginal gel was inserted three times per week at bedtime for 12 weeks.  
The vaginal pH-balanced gel was shown to have a significant effect on vulvovaginal dryness and 
dyspareunia (Yoo-Kyung, et al., 2011). The gel also lowered vaginal pH, significantly increased 
the vaginal maturity index, resulted in high rates of symptom relief, and demonstrated minimal 
side effects (Yoo-Kyung, et al., 2011).  This suggests that vaginal pH-balanced gel can be a well-
tolerated and effective regimen for breast cancer survivors who may experience vaginal 
atrophy (Yoo-Kyung, et al., 2011).  
Pilocarpine, a nonselective muscarinic receptor agonist has been found to increase 
vaginal mucus with a reduction in vaginal dryness (Pruthi, et al., 2011).  The botanical formula 
has demonstrated stimulation of sensory nerve conduction and improvements in sexual 
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function in postmenopausal women.  This formula includes ingredients such as borage seed oil, 
evening primrose oil, angelica extract, coleus extract, vitamin C, and vitamin E. The use of 
lidocaine ointment 5% and gabapentin cream 6% may also be helpful in the management of 
dypareunia (Pruthi, et al., 2011).   
Localized Vaginal Estrogen 
Localized vaginal estrogens are more effective for atrophic vaginitis than systemic 
estrogen replacement alone. They restore the vaginal mucosa through a binding action on the 
estrogen receptors within the vaginal epithelium.  The initial degree of systemic absorption is 
low due to the atrophic vaginal epithelium but increases secondary to the improvement in 
vascularity through ongoing treatment (Castel-Branco, et al., 2005).  These formulations also 
increase the release of nitric oxide, which increases blood flow to the urogenital area (Carcio, 
2002).  
Overall, the administration of exogenous estrogen restores vaginal pH with a positive 
effect on the thickening and revascularization of the epithelium (Ibe & Simon, 2010).  
Secondary to these anatomic improvements, local estrogen therapy increases lubrication and 
has a positive effect on the vaginal maturation index with an increase in the level of superficial 
cells. The increased vascularization of the lower urogenital tract alleviates symptoms of 
dryness, irritation, pruritis, urinary urgency, and dyspareunia. These changes can improve 
quality of life, sexual desire, arousal, and orgasmic function (Castelo-Branco, et al., 2005; Ibe & 
Simon, 2010).   
Systemic absorption of localized estrogen therapy 
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 More systemic absorption is seen with low dose estrogen creams compared to the 
vaginal tablets and low-dose vaginal rings (Pruthi, et al., 2011).  A study that investigated low 
dose estrogen therapy in breast cancer survivors compared the results of a low dose vaginal 
cream, a vaginal tablet, and a non-hormonal moisturizer (Biglia, et al., 2010). Vaginal estrogen 
therapies were equally effective in relieving vaginal atrophy in postmenopausal breast cancer 
survivors whereas only a transient benefit was obtained with the use of a non-hormonal vaginal 
moisturizer on subjective and objective measures of vaginal health (Biglia, et al., 2010).  After 
12 weeks of vaginal estrogens, serum levels of E2 in women treated with estradiol tablets 
increased 2.7pg/mL whereas women that used estradiol cream had a 3.5 pg/mL change (Biglia, 
et al., 2010).  
Three studies have compared the systemic absorption of lower (10 µg twice per week) 
versus standard doses (25 µg twice per week) of vaginal E2 tablets in postmenopausal women. 
All arms demonstrated comparable results after three months of treatment, with c irculating E2 
levels that remained within the postmenopausal range of 3-10 pg/mL (Biglia, et al., 2010).  It is 
rationalized that these similar increases of circulating plasma estrogens might not exert a 
negative effect in women with breast cancer, especially if they receive simultaneous tamoxifen 
due to its competitive interaction with estrogen receptors (Biglia, et al., 2010).  
Nevertheless, it still cannot be concluded that even a small increase in systemic 
estrogens may be detrimental in women receiving AIs; an ultra-low estrogen treatment needs 
to be studied in the future (Biglia, et al., 2010).  Future treatment for women on AIs may 
include a combination of vaginal estrogens with tamoxifen for a short term interval, followed by 




Vaginal administration of testosterone has been evaluated for symptomatic treatment 
of urogenital atrophy. When taken with aromatase inhibitors, testosterone-induced 
proliferation of the vaginal epithelium occurs, but the AI blocks the conversion of systemic 
levels of testosterone to estrogen.  A phase I/II pilot study to assess whether vaginal 
testosterone affected estradiol and testosterone levels in breast cancer patients on AIs was 
conducted.  The intravaginal cream contained either 150 µg or 300 µg of testosterone and 
demonstrated no significant affect on before and after circulating estradiol levels (Witherby, et 
al., 2011).  The study did find that circulating testosterone levels were slightly increased.  The 
severity of dyspareunia and vaginal dryness improved significantly with treatment; a smaller 
degree of improvement sustained one month after completion of treatment (Witherby, et al., 
2011).  The study also documented that the vaginal maturation index increased, the vaginal 
environment became more acidic, there was a greater degree of lubrication, a color change 
from white to pink, and evidence of rugae formation (Witherby, et al., 2011).  The two doses 
did not differ significantly in improvement of clinical symptoms, however the pathologic 
measurements did. There was a 60% higher maturation index with the 300 µg dose as 
compared to a 20% increase with the 150 µg dose. A significant decrease in pH as compared to 
baseline was also seen with the 300 µg dose whereas the 150 µg dose did not have the as 
significant effect (Witherby, et al., 2011). 
 Intravaginal administration of dehydroepiandrosterone (DHEA) has also been under 
investigation as a treatment for vaginal atrophy.  The supplementation of DHEA allows for the 
biosynthesis of androgens and estrogens in specific targeted tissues such as those in the vagina 
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which contain the required enzymes for conversion. Very low levels of this steroid are found in 
the circulation because they exert their action on the same cells where they are formed.  This 
form of treatment has been shown to increase the vaginal maturation index and decrease the 
pH in the vagina without increasing the level of circulating estrogen (Ibe & Simon, 2010). 
 A randomized double-blind placebo-controlled trial measured serum levels of 
dehydroepiandroesterone (DHEA) after daily intravaginal administration of one of four 
concentrations during a 12 week period in postmenopausal women (Pruthi, Simon, & Early, 
2011).   The study found that vaginal administration of DHEA was efficient in treating urogenital 
atrophy with no or minimal changes in serum levels of DHEA over those 12 weeks (Pruthi, et al., 
2011).  A recently completed trial also found intravaginal dehyroepiandrosterone (Prasterone™) 
to be effective on vaginal atrophy without elevation of estradiol or testosterone levels above 
usual postmenopausal levels (Witherby, et al., 2011).    
 Testosterone therapy has been associated with higher frequency of sexual activity, 
increased interest, desire and enjoyment, increased arousal, and increased pleasure (Castelo-
Branco, et al., 2005).  Data on the effects of increased levels of testosterone levels is still lacking 
and it is important to determine the lowest effective and least worrisome dose of testosterone 
in this population.  The association between testosterone therapy and elevated serum 
testosterone levels with initial and recurrent breast cancer is still controversial and several 
studies suggest that a possible greater breast cancer risk associated with testosterone is 




Complementary and alternative products have been studied to determine their effects 
on vulvovaginal atrophy.  One study noted that Vitamin E and phytoestrogen in localized gel 
preparation improved the symptoms of vulvovaginal atrophy (MacBride, et al., 2010).  Studies 
document that women who did not take oral Vitamin D supplementation had significantly 
higher symptomatic rates of vulvovaginal atrophy and negatively affected vaginal maturation 
indices (Calleja-Agius & Brincat, 2009; MacBride, et al., 2010).  A soy rich diet has also been 
investigated for the treatment of urogenital atrophy (MacBride, et al., 2010; Manonai, 
Songchitsomboon, Chanda, Hong, & Komindr, 2006).  Soy is a phytoestrogen that has structural 
similarities to natural and synthetic estrogens; it binds to estrogen receptors in the vagina and 
the bladder. It does not exert a positive effect on the maturation of the vaginal epithelium 
(MacBride, et al., 2010; Manonai, et al., 2006).  
Additional Studies 
Despite the positive effects of localized estrogen therapies on atrophic vaginitis, there 
remains a concern of systemic side effects from circulating levels of estrogen.   Investigation of 
estrogen agonists/antagonists is ongoing as these non-steroidal compounds can have a 
proliferative effect on vaginal tissue (Ibe & Simon, 2010).  Raloxifene and tamoxifen are two 
estrogen agonists/antagonists that are used in the chemoprophylaxis of breast cancer.  Neither 
of these treatments has demonstrated a positive or detrimental effect on vaginal tissue in 
postmenopausal women.  Other estrogen agonists/antagonists such as lasofoxifene and 
ospemifene have a positive effect on vaginal tissue in postmenopausal women. Currently in 
phase III trials, the selective estrogen receptor modulator (SERM) lasofoxifene has 
demonstrated decreased vaginal pH, increased maturational index of the vaginal epithelium, 
17 
 
stimulated vaginal mucous formation, and improved dyspareunia in postmenopausal women 
(Calleja-Agius & Brincat, 2009; Ibe & Simon, 2010).  Ospemifene is under study in phase III trials 
for vaginal atrophy.  Twelve weeks of treatment with Ospemifene was found to improve vaginal 
dryness and dyspareunia without any observed proliferative effects  on the endometrium (Ibe 
& Simon, 2010).   
Atrophic Vaginitis in Breast Cancer Survivors 
Hormonal products, whether oral or vaginal, are effective in reducing symptoms of 
atrophic vaginitis; however, oral hormonal products are contraindicated in women with a 
breast cancer history.  The safety profile of vaginal estrogen products remains in question 
secondary to a possible mediating effect on breast cancer recurrence (Pruthi, et al., 2011).  Safe 
and reliable interventions for atrophic vaginitis are needed to effectively reduce these 
disruptive symptoms and improve the quality of life in breast cancer survivors.  Omega 3 fatty 
acids may address atrophic vaginitis through suppression of inflammation with restoration of 
tissue integrity and elasticity. Omega 3 fatty acids have the ability to exert these changes and 
provide protective healing properties (McDaniel, Massey, & Nicolaou, 2011) with effective 
treatment of atrophic vaginitis. 
Omega Three Fatty Acids 
Wound Healing 
Wound healing is a complex process that involves multiple stages.  In the inflammatory 
stage, molecular and cellular processes are initiated by a group of protein mediators known as 
proinflammatory cytokines (McDaniel, Belury, Ahijevych, & Blakely, 2008).  These 
proinflammatory cytokines include interleukin-1β, interleukin-6, and tumor necrosis factor-α 
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that are secreted by neutrophils, macrophages, mast cells, fibroblasts, and endothelial cells. 
This release of cytokines signals biological processes during the inflammatory stage of wound 
healing and binds to receptors on target cells (McDaniels, et al., 2008). This activity of the 
cytokines works to assist infection control and prepare tissue for further repair by increased 
phagocytic activity, stimulated keratinocyte migration at wound edges, proliferation, 
breakdown of extracellular proteins, and regulation of the release of additional cytokines and 
growth factor (McDaniel, et al., 2008).   
The activity and synthesis of the proinflammatory cytokines are affected by the 
concentration of ω-3 polyunsaturated fatty acids (PUFA), eicosapentaenoic acid (EPA), and 
docosahexaenoic acid (DHA) which are primarily found in fish oil, plasma, tissue, and cellular 
membranes (McDaniel, 2008).  The ω-6 arachidonic acid (AA) and the ω-3 EPA are released 
from the phospholipid layer of cellular membranes in response to wound healing with the EPA 
of preferential state (McDaniel, et al., 2008).   
EPA and DHA are also thought to have an effect on the gene expression of 
proinflammatory cytokines at the level of transcription (McDaniel, et al., 2008). A recent study 
was completed on healthy individuals to test the effect of omega 3 oil on cutaneous wound 
healing.  The dietary supplementation of ω-3 (EPA/DHA) fatty acids was tested to observe the 
amount of cytokines present in the wound exudate in association with a healed wound 
compared to effects in the placebo group.  The study found that in the intervention arm, there 
was a decreased plasma AA:EPA ratio from baseline, non-significant slower wound healing, and 
a higher production of Interleukin-1β 24 hours after the blister wound was initiated as 
compared to the placebo group who took mineral oil.   Even though the wound healing was 
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observed to be slower in the intervention group, there was still evidence to demonstrate that 
dietary ω-3 PUFA affects the local production of inflammatory cytokines that regulate the 
wound healing process (McDaniel, et al., 2008).   
Chronic wounds can result from prolonged inflammation and include excessive 
polymorphonuclear leukocyte (PMN) activity (McDaniel, et al., 2011).  Inflammation is an 
essential initial stage of tissue regeneration but when prolonged, can delay advancement to 
subsequent healing stages.  The high amounts of PMNs secrete excessive amounts of proteases 
that can cause tissue destruction and persistent inflammation (McDaniel, et al., 2011).  The 
bioactive lipid mediators derived from the long-chain n-3 polyunsaturated fatty acids (PUFA) 
eicosaentaenoic acid (EPA) and docosahexaenoic acid (DHA) acids have demonstrated a 
reduction in inflammatory responses and PMN transmigration across the endothelium 
(McDaniel, et al., 2011).  Epidemiological studies report clinical improvements in a number of 
chronic inflammatory diseases with diets rich in n-3 PUFAs that contain EPA and DHA 
(McDaniel, et al., 2011).  This has been observed by anti-inflammatory actions in disease 
models such as peritonitis, colitis, and peridontitis (McDaniel, et al., 2011).   
In a study of n-3 PUFA oral supplements on cutaneous blister wounds, researchers 
noted that fish oil supplements raised the levels of EPA and DHA and reduced both the total  
n-6:n-3 and AA:EPA ratios from baseline values (McDaniel, et al., 2011).  The study noted that 
the addition of EPA and DHA caused a suppression of the proinflammatory mediators at the 
wound site as well as increases in the anti-inflammatory mediators.  EPA was found to reduce 
the recruitment of leukocytes and neutrophils to wound sites 12 hours after the blister wound 
was initiated (McDaniel, et al, 2011).  The data demonstrated that EPA made it possible to 
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manipulate systemic levels of lipid mediators associated with inflammation reduction. This 
would be a beneficial supplementation in the case of heightened or prolonged inflammatory 
responses such as chronic wounds or trauma (McDaniel, et al., 2011).   
The data from this study strengths the hypothesis that EPA has a positive effect on the 
local tissue level through alteration of the anti-inflammatory pathways (McDaniel, et al., 2011).  
The EPA demonstrated a rise in the anti-inflammatory mediators that include resolvins and 
protectins with strong anti-inflammatory PMN regulatory actions (McDaniel, et al., 2011).  This 
action promotes wound epithelialization and inflammatory resolution. The study suggested that 
EPA and DHA affect the levels of local and systemic lipid mediators that can be adjusted to 
encourage inflammation resolution, PMN down-regulation, and wound re-epithelialization 
(McDaniel, et al., 2011).   
Use of Omega 3 in Atrophic Vaginitis 
The consideration of fish oil as an appropriate treatment for breast cancer survivors 
must include the risk of recurrent disease. Studies in animals have demonstrated that long 
chain n-3 fatty acids present in high levels of fish oil, have protective effects against several 
tumor types, including mammary tumors (Goodstine, et al., 2003).  Conversely n-6 fatty acids, 
an unsaturated fatty acid which is very popular in American diets, enhanced mammary 
carcinogenesis in animal models (Goodstine, et al., 2003).   
Americans generally consume relatively low amounts of n-3 fatty acids in their diets, 
whereas the population of Greenland Eskimos consumes considerable amounts.  Even though 
their diets consist of a high amount of fat, the breast cancer rate is very low in this population 
(Bang & Dyerberg, 1980; Goodstine, et al., 2003) due to consumption of high level of n-3 vs. n-6 
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fatty acids.  The Japanese also consume a high amount of omega-3-rich fish (n-3 PUFAs) and 
their breast cancer incidence rates are also very low (Goodstine, et al., 2003).  A recent study in 
Connecticut found that the consumption of a higher n-3:n-6 PUFA intake ratio was associated 
with a lower risk of breast cancer in US women. In premenopausal women researchers noted 
that increased n-3/n-6 PUFA ratios resulted in a 41% decrease in breast cancer occurrence and 
an 11% decrease in odds of breast cancer in postmenopausal women (Goodstine, et al.,  2003). 
Other studies have found even stronger inverse associations with breast cancer in 
postmenopausal women who consumed high amounts of n-3 PUFAs (Goodstine, et al., 2003).    
Omega 3 Study in Breast Cancer Survivors with Atrophic Vaginitis 
 A study of the effects of omega 3 fatty acid oral supplementation on signs and 
symptoms of atrophic vaginitis in breast cancer survivors was proposed based on the 
compendium of previously mentioned studies. The associations of predominantly EPA-derived 
benefits of wound healing of skin tissues (Figure 3) to the cascade of events in treatment-
induced or exacerbated menopausal vaginal atrophy directed attention to the potential effects 
of omega 3 oral supplementation.  
Study Design 
 A randomized, double blind Phase II screening trial was proposed to determine the 
effect of omega 3 fatty acids on atrophic vaginitis in postmenopausal breast cancer survivors. 
This institutional-approved review board (IRB) study was derived to improve our current 
knowledge about symptoms of atrophic vaginitis in postmenopausal breast cancer survivors, 
and to provide baseline data about whether oral omega-3 fatty acid oral supplementation can 
decrease inflammation and improve self-reported and observed outcomes.  Postmenopausal 
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breast cancer survivors (N=52) with one or more complaint(s) of atrophic vaginal atrophy (e.g. 
vaginal dryness, genital irritation/itching, genital pain, or dyspareunia) were randomized to oral 
omega-3 supplementation or a matched placebo. Interim analyses of completed cases were 
planned for purposes of this undergraduate thesis. 
Purpose and Specific Aims 
The purpose of this study was to explore whether omega-3 fatty acids can improve 
atrophic vaginitis in postmenopausal breast cancer survivors.   
Primary Aim #1:  To explore whether oral omega-3 fatty acids can improve self-reported 
symptoms related to atrophic vaginitis in postmenopausal breast cancer survivors. 
Primary Aim #2:  To explore whether oral omega-3 fatty acids can decrease inflammation 
related to atrophic vaginitis in postmenopausal breast cancer survivors. 
Sample Size and Eligibility Criteria 
For this screening trial, the sample size was estimated based on the number of 
participants necessary to observe a measureable improvement in self-reported symptoms of 
pain or discomfort.  The sample size was identified through a power analysis, considering a 
large effect (0.8 of a within group standard deviation) with 80% power at α-level of .05.  As an 
approximation to the sample size, we used a t-test for two independent samples with a two-
sided test.  To achieve the desired goals, 26 subjects were studied in each treatment group, for 
a total N of 52.  Improvements in symptom profiles on the self-report instruments were sought 
as proxy measures of pain and discomfort related to atrophic vaginitis.  As secondary outcome, 
vaginal pH and maturation index were utilized as a proxy measure of inflammation related to 
atrophic vaginitis.  A reduction of 1.0-1.5 in vaginal pH will be considered clinically significant as 
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an improvement in inflammation related to atrophic vaginitis , although the potential effects of 
omega 3 fatty acids on markers of atrophic vaginitis were relatively unknown prior to the study 
start. Improvements of symptoms on one or more self-report instruments were considered 
indicative of a positive effect from the intervention. 
The following inclusion criteria were used for study eligibility: female, between the age 
of 45-65 (later amended to 35-70), a personal history of Stage 0, I, II, or III breast cancer, at 
least 12 months from definitive surgical procedure, completion of chemotherapy, 
postmenopausal (e.g. defined as no menstrual cycle for 12 consecutive months, or surgical 
menopause), no current use of estrogen replacement therapy or estradiol-releasing vaginal ring 
or tablets, no evidence of disease (NED) of any cancer or breast cancer, no current use of oral 
omega 3 fatty acids (e.g. if recent consistent use of these products, off at least six months; if 
sporadic use of these products, off at least 3 consecutive months ), Eastern Cooperative 
Oncology Group (ECOG) performance status of 0 or 1, no history of a bleeding tendency, 
uncontrolled hypertension, heart disease or stroke, and normal hematopoietic and liver 
function studies (e.g. hemoglobin > 10g/dL, hematocrit > 30%, white blood count > 3.5K/uL, 
platelet count > 100,000/mm3, fasting serum glucose < 115mg/dL, total bilirubin < 1.6mg/dL, 
and liver transaminases < 1.5 x upper limits of normal). Potential participants could be 
prescribed with current use of oral anti-estrogens (e.g. tamoxifen or raloxifene), aromatase 
inhibitors (e.g. letrozole, exemestane, or anastrozole), or biologic therapy (e.g. continuation of 
adjuvant treatment with targeted agents).  
Potential candidates were excluded from the study secondary to: metastatic malignancy 
of any kind, ongoing chemotherapy or radiation therapy (ongoing hormonal therapy and/or 
24 
 
biologic therapy were allowed), history of pelvic or genital radiation therapy, use of Coumadin 
or other anticoagulants, known active pelvic, vaginal, or urinary tract infections, current use of 
systemic or local applications of hormone replacement therapy, uncontrolled co-morbid 
conditions (e.g. ongoing or active infection, symptomatic congestive heart failure, unstable 
angina pectoris, or unstable hypertension), psychiatric illness or social situation that would limit 
comprehension or adherence to study requirements, consistent use of omega-3 fatty acid 
concentrates or capsules within the 6 months prior to entry on the study, a known sensitivity or 
allergy to fish oil or omega 3 fish products, and subjects who could not give an informed 
consent.   
Methods 
Study Enrollment and Signed Consent 
After explanation of the study, written informed consent, and verification of baseline 
study lab values, participants were randomized to one of two treatment arms: 3.5g of oral 
omega 3 fatty acids per day or matched placebo capsules. The participants were instructed to 
take 7 capsules per day in (at least) two divided doses for a 6-month period.   
Study Measures 
Participants were required to complete a study visit at baseline, three- and six-months. 
At each visit the participant completed self-report symptom surveys, provided serum and 
vaginal samples, and underwent a vaginal exam completed by the study gynecologist (156 total 
exams for study). At the baseline visit participants were asked to complete a breast health 
history form and initial self-report questionnaires. These questionnaires included the Urogenital 
Atrophy Questionnaire (UAQ), The Female Sexual Function Instrument (FSFI), Menopause 
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Rating Scale (MRS), Center for Epidemiologic Studies in Depression Scale (CES-D), and Brief Pain 
Inventory (BPI).  
Vaginal examination 
The vaginal examination included subjective and objective evaluation of external genital 
pain and discomfort, visual examination, and vaginal swab for biologic markers  that 
represented vaginal state (e.g. maturation index, parabasal level) and cytology.  The 
gynecologist observed and noted the color of the vaginal mucosa, amount and color of 
secretions, presence or absence of rugae, introitus elasticity, appearance of the introitus, 
appearance of the labia majora and the labia minora, color of the external genitalia, presence 
of any bleeding tendencies (e.g. petechiae, friability) of the vaginal tissue, presence or absence 
of pubic hair, presence or absence of urethral caruncle(s), and the participant’s rating of the 
pain upon touch to the vestibule with a cotton swab. During the examination, the practitioner 
obtained a sample from the distal two-thirds of the lateral vaginal wall (e.g. avoiding the 
posterior fornix and cervix) for calculation of vaginal pH on phenaphthazine paper with a color-
coded range of 4.5-7.5.  A reading of 5.0 or greater was indicative of atrophic vaginitis.  A wet 
mount was concurrently performed by the gynecologist to identify the presence or absence of 
vaginal yeast or bacterial infections that may alter the vaginal pH.   
 After completion of the genital examination by the gynecologist, the participant 
obtained a self-pH; practitioner-obtained vaginal pH and patient-obtained self-pH were 
compared as reliability measures in preparation for future cooperative group studies using a 




At the baseline visit, a fasting blood draw was obtained to evaluate a complete blood 
count (CBC), fasting serum glucose, total bilirubin, and liver transaminates to document normal 
hematopoietic and liver function. Serum ALT values were tested at subsequent 3- and 6-month 
visits as toxicity measures. At study end, additional serum evaluations are planned to verify 
serial hormonal levels, and measures of inflammation including cytokines.  All labs with the 
exception of eligibility and toxicity measures will be completed at study end in order to batch 
samples and match lot numbers for specific lab tests. 
Self-report symptom profiles 
The self-report questionnaires were provided at each visit and study participants were 
also requested to complete them at monthly intervals; a self-addressed, stamped mailing 
envelope was provided for return to study personnel. Each month the participants received a 
monthly reminder call to document adherence based on current capsule counts, remind the 
participant to mail completed monthly self-report instruments, and to note any experienced 
side effects from the study drug. A paper daily medication diary was distributed at the 
beginning of the study to provide participants with a document to note daily adherence 
patterns and any experienced side effects (e.g. mild gastrointestinal discomfort, fishy 
aftertaste, belching, nausea, flatulence or loose stools , or other). A participant:study personnel  
pill count was also documented at 3- and 6-month visits, with participant-reported pill counts at 
months 1, 2, 4, & 5.   
Additional study measures 
Food diaries were utilized to note patterns of dietary intake of all foods and fatty acids.  
Measures of dietary intake included the Fred Hutchinson Food Frequency Questionnaire (FFQ) 
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at baseline and six months, and three-day food diaries at baseline, three-, and six-month 
intervals.  The FFQ obtained a six-month recall of dietary patterns prior to the start, and at the 
end of the study period; the three-day food diaries obtained real-time records of meal and 
snack content that was consumed at baseline, and on or about three days before the three- and 
six-month visits (Newhouser, et al., 2008; Olafsdottir, Thorsdottir, Gunnarsdottir, 
Thorgeirsdottir, & Steingrimsdottir, 2006).  Measures of height, weight, body mass index (BMI), 
waist, and hip circumference, and waist-to-hip ratio (WHR) were obtained to note differences 
in body composition amongst participants and across the study period (Behan & Mbizo, 2007).   
Data Analyses and Interpretation 
 
 This interim study analysis was conducted to inform the study team and reader of 
potential outcomes after enrollment, study completion, and confidential reveal of intervention 
for approximately 75% of study participants. The data represented here illustrates a brief 
examination of isolated study parameters in association with the revealed study intervention, 
such as vaginal parabasal level and pH, and selected self-report symptom profiles. 
Interpretations of these data were limited to current research student interest and trends; full 
interpretation and disclosure of the data will occur at study completion with evaluation of all 
measurement and study parameters.  
Primary Aim: Self-Report Symptoms 
Primary Aim #1:  To explore whether oral omega-3 fatty acids can improve self-reported 
symptoms related to atrophic vaginitis in postmenopausal breast cancer survivors. 
The data obtained from the self-report questionnaires was partially analyzed and scored in the 
standard fashion relative to selected instruments in order to compare differences in scores 
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across different time points.  Descriptive statistics were used. The goal was to compare 
differences in scores across different time points, including mean severity at baseline and the 
change in mean severity between baseline, midpoint (3 months) and end (6 months) of 
treatment.  
Repeated measures ANOVA models (in future will include covariates) were fitted to the 
data.  Separate models will be fitted for each of the scales used to measure outcomes of the 
study.  In each case, time was used as a within-subjects variable, treatment (placebo and 
intervention) was used as a between-subjects variable, and subject was used as a random effect 
nested within treatment.  Time and treatment were interacted to allow for different treatment 
effects between the groups over time.  Through examination of appropriate contrasts, we will 
be able to determine whether there is a significant effect of the drug on the outcome 
measure(s) at each time point.  This model will be augmented with covariates, such as 
demographic variables, systemic breast cancer treatment, body habitus measurements, dietary 
intake pertinent to foods rich in omega 3 fatty acids, and/or serum hormone levels. 
Urogenital atrophy questionnaire  
The Urogenital Atrophy Questionnaire (UAQ) is a 15-item questionnaire designed and 
validated as a brief, self-report instrument to assess unpleasant symptoms related to urogenital 
atrophy, including vaginal dryness.  Responses are numerically weighted with an additive 
scoring system that allows assessment of function, satisfaction, pain, and urogenital quality of 
life in three domains (urologic, genital, and sexual) and ten factors:  urinary incontinence, 
changes in urinary patterns, burning with urination, genital itching/odor, genital irritation, 
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vaginal discharge, pain with sexual activity, interest/desire in sexual activity, partner 
communication, and sexual activity without genital touching (Lester, et al., 2012). 
Female sexual function index 
The Female Sexual Function Index (FSFI) questionnaire is a 19-item questionnaire 
designed and validated as a brief, self-report instrument to assess female sexual function and 
quality of life in clinical trials.  Responses are numerically weighted and easily converted to a 
scoring system that allows assessment of six different areas:  desire, arousal, lubrication, 
orgasm, satisfaction, and pain (Rosen, et al., 2000).   
Menopause rating scale 
The Menopause Rating Scale (MRS) (Heinemann, et al., 2004) is a brief, self-report, 
health-related quality of life scale with eleven items.  This scale was designed and validated to 
measure common menopausal symptoms.  It is validated to measure treatment effects on 
quality of life using numerically weighted items with an additive scoring system.  The MRS 
includes three subscales:  psychological, somatic, and urogenital.  Scores of each subscale, as 
well as total subscale can be evaluated (28, 29). 
Depression Short Scale 
The Center for Epidemiologic Studies Depression Short Scale (CES-D10) is a brief, 10-
item self-report depression symptoms index.  This instrument was designed to assess the 
presence and severity of depressive symptoms as noted in the past week.  It is validated in 
breast cancer survivors (mean age 56.1) in a study to assess psychosocial adjustment and 
quality of life (Carpenter, et al., 1998).  The CES-D10 used numerically weighted items with an 
additive scoring system (Carpenter, et al., 1998).  
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Potential Pitfalls:  In the case of incomplete questionnaires, patients were approached by 
nursing or study personnel during clinic visits to clarify any question or concerns regarding 
specific items on the form.  Telephone contacts were utilized to encourage completion of the 
monthly study questionnaires. 
Primary Aim: Vaginal Milieu and Inflammation    
Primary Aim #2:  To explore whether oral omega-3 fatty acids can decrease 
inflammation related to atrophic vaginitis in postmenopausal breast cancer survivors.   The data 
obtained from the vaginal pH results was partially analyzed and scored in accordance with the 
scale and color range supplied by the manufacturer.  Differences in scores between different 
time points were compared using descriptive statistics.  Repeated measures ANOVA models 
were fitted to the data.  Separate models will be fitted for each of the scales being used as 
outcomes of the study.  In each case, time was used as a within-subjects variable, treatment 
(placebo and intervention) was used as a between-subjects variable, and subject was used as a 
random effect nested within treatment.  Time and treatment was interacted to allow for 
different treatment effects between the groups over time.  By examining the appropriate 
contrasts with the full data set, we will be able to determine whether there was a significantly 
different effect of the study drug on the outcome measures at each time point.  This model will 
be augmented with covariates, such as demographic variables, systemic breast cancer 
treatment, body habitus measurements, dietary intake pertinent to foods rich in omega 3 fatty 
acids, and/or serum hormone levels. 
Potential Pitfalls:  In the event of a vaginal or urinary tract infection at the three- or six-month 
visits, the pH will be obtained one week after resolution of the problem. During the study 
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period, only one (resolving) yeast infection was noted, and not other vaginal infections or 
abnormalities were noted with the exception of vaginal warts at the six-month evaluation of 
one candidate. It was anticipated that vaginal pH would improve as a measure of physiologic 
improvement and healing of the parabasal layer, as evidenced in studies with other agents  
although no studies had previously measured the effect of omega 3 on vaginal pH. 
Analyses of Data 
 Preliminary analyses were conducted of 40 participants that were unblinded by the 
scientific study pharmacist at the end of April 2012. These participants had completed all 
components of the study and were no longer active participants. Examination and analyses of 
data were limited to physiologic biomarkers related to the vaginal examination, and limited 
self-reported items. 
Vaginal Environment 
 Limited analyses of the vaginal environment demonstrated few changes. Individual 
items from the vaginal assessment sheet were evaluated at T0, T3, and T6 time points. Using 
analysis of variance (ANOVE) there were no significant findings on vaginal pH, self-reported 
sexual problems, urinary problems, or vaginal dryness in comparison of the two study arms: 













Figure 2. Analyses of T6 items 
ANOVA 
 Sum of Squares df Mean Square F Sig. 
T6 vaginal pH Between Groups 1706.907 1 1706.907 1.128 .295 
Within Groups 57516.193 38 1513.584   
Total 59223.100 39    
T6 MRS sexual problems Between Groups 63.375 1 63.375 .050 .825 
Within Groups 48589.600 38 1278.674   
Total 48652.975 39    
T6 MRS bladder problems Between Groups 49.307 1 49.307 .038 .847 
Within Groups 49425.093 38 1300.660   
Total 49474.400 39    
T6 MRS dryness of vagina Between Groups 166.427 1 166.427 .116 .735 
Within Groups 54327.173 38 1429.662   
Total 54493.600 39    
 
 Of interest are several variables that were statistically significant.  Chi-square was used 
to analyze uneven groups (placebo, n=15, omega 3, n=25) in this preliminary analyses. There 
was a statistically significant difference between the two study groups at time period ‘6 
months’ for presence/absence of rugae (p=0.063) and presence/type of bacteria (p=0.021) in 
the intervention arm with omega 3 capsules.  In addition, the self-report item on the Urogenital 
Atrophy Questionnaire ‘thought of pain with sexual activity’ was statistically significant likewise 
in the intervention arm at time period ‘3 months’ (p=0.015) and ‘6 months’ (p=0.016). Of note, 
at baseline, there was no significance between the groups (p=0.770). 
 These findings in these preliminary analyses of data appear promising in that perhaps a 
perceived decrease is present for ‘anticipated pain with sexual intercourse’, as well as positive 
correlations for two biologic markers. Detailed statistics over time between and within the 
groups were not conducted; perhaps additional positive findings will be noted at the time of 




Breast cancer is the most common cancer diagnosed among women. Therefore, it is 
anticipated that complaints of symptoms related to vaginal atrophy will become more frequent 
in the clinical setting. In addition, the number of survivors is exponentially increasing, and the 
use of aromatase inhibitors has significantly increased over the last decade. Therefore, the 
short- and long-term side effects related to atrophic vaginitis will likely be present, as indicated 
by previous studies (Lester, et al., 2012).  
This study was designed to measure a non-hormonal intervention that would provide an 
optimal treatment option for those breast cancer survivors who suffer from vaginal dryness, 
irritation, and dyspareunia. The women on the study were very compliant with the daily drug 
regimen, completed monthly surveys and attendsx study visits at 0, 3, and 6 months. A pelvic 
examination with a visual exam of the external and internal surfaces was completed at each of 
the visits as well as the battery of self-reported symptom instruments. 
Physiological Findings 
It was hypothesized that omega 3 could make a significant change in physiological 
determinates of atrophic vaginitis such as vaginal pH or cellular maturity.  An interim analysis of 
the data was completed which included 40 of the participants. At that time, the placebo group 
had 15 participants and the omega group consisted of 25 participants. The level of cellular 
maturation was determined by each visit’s cytologic examination of the vaginal smear from the 
upper one-third of the vagina. The vaginal pH, bacteria, external and internal properties were 
also analyzed as outlined on the vaginal examination sheet. Limited items of the participants’ 
responses in the self-report questionnaires were analyzed to determine whether there were 
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any significant differences between the two treatment groups in terms of subjective symptoms.  
With a 95% confidence interval, the interim analysis (n=40) found a significant change in 
bacteria from baseline to the 6 month visit for the omega group (p= 0.021). This indicates that 
the bacteria in the Omega group demonstrated a significant trend toward lactobacilli growth in 
the vaginal environment. The growth of lactobacilli indicates that the vaginal environment is 
producing the bacteria found in normal estrogenized women. The lactobacilli bacteria will 
produce lactic acid and facilitate a more protective acidic environment.  
The omega group also had a significant change in the presence of rugae from baseline to 
6 months (p=0.063). This may indicate that the vaginal walls of the omega group are able to 
now form protective layers. This would lead to an increase in resilience and a decrease in 
irritation, friability, tearing, and ulcerations with friction or sexual intercourse.  
Self-Reported Items 
Observation of items on the Urogenital Atrophy Questionaire (UAQ) indicated that the 
omega 3 group had a significant change in concern with their anticipated worry about pain with 
sexual intercourse. This significant change was seen at 3 and 6 month visits (p=0.015 and 
p=0.016, respectively).  In concert with the previous findings, the omega 3 group may 
experience less pain with intercourse due to a more protective acidic environment and the 
formation of rugae which provides a protective layer.  Recalculation of these findings will occur 
with the full data set upon completion of the study to determine if these positive findings 
persist.  
In regard to self-reported ‘vaginal dryness’, a significant change was seen among the 
omega 3 group at the 6 month interval (p=0.129 with a 90% confidence interval). This trend 
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toward a positive effect provides data to ponder until the entire data set is completed and 
ready to examine in full. But, these promising findings in the omega 3 study arm provide 
enough data to summarize that the omega 3 group experienced a decrease in anticipatory pain 
experienced with sexual intercourse.  
These findings in these preliminary analyses indicate that the use of omega 3 for 
atrophic vaginitis in breast cancer survivors may have the potential to improve the vaginal 
epithelium and decrease the self-reported symptoms of dryness and dyspareunia. In the future, 
an analysis will be completed on the entire data set (N=52) and further potential mediated 
effects of the omega 3 will be determined. 
Implications for Practice 
It is hopeful that a simple non-hormonal intervention such as omega 3 fatty acids oral 
supplementation will improve self-reported symptoms, decrease inflammation, and improve 
the vaginal environment related to atrophic vaginitis in postmenopausal breast cancer 
survivors. If these finding are not statistically evident, further research will be necessary to 
identify an optimal treatment for these unpleasant symptoms in breast cancer survivors. 
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